Single and Multiple Ascending Doses of NTX-253 in Healthy Participants and Participants With Stable Schizophrenia

Recruiting Early Phase 1 Interventional Study
Healthy Participants Schizophrenia Diagnosis
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Healthy Volunteers Welcome You do not need to have the condition being studied to take part.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 – 55
Sex
Any
Trial phase
Early Phase 1
Study type
Interventional
Purpose
Treatment
Participants needed
73 (estimated)
Sponsor
Neurosterix · Industry
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

This study will assess the safety, tolerability, and pharmacokinetics of NTX-253 following oral administration in both healthy adult participants as well as adult participants with stable schizophrenia.

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Primary Inclusion Criteria: * Male or non-pregnant, non-lactating female participants, ages 18-55 who are not of childbearing potential, with a truly abstinent lifestyle, or agrees to use medically acceptable forms of birth control * Part 1 a/b, Part 2 Cohort 7 only: Body mass index (BMI) within th…
Contacts

Doug Feltner, Chief Medical Officer, MD

+41 22 884 15 55

doug.feltner@neurosterix.com

CONTACT

Lisa Corey

+41 22 884 15 55

lisa.corey@neurosterix.com

CONTACT